Trending...
- Report: Chicago's Safety Plan Showing Promising Results in Key Neighborhoods
- Naperville: Annual Arbor Day Tree Sale Begins Online at 8 a.m. March 23
- CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capabilities of a technology company with those of a biopharmaceutical company, the two companies hope to advance drug discovery and development, to more quickly deliver innovation to patients.
The strategic collaboration aims to optimize Tempus' AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale. Under the terms of the agreement, AstraZeneca will leverage Tempus' de-identified data and analytical tools across a broad range of capabilities. This collaboration combines Tempus' AI and machine learning capabilities for identifying novel insights with AstraZeneca's deep expertise in R&D to ultimately develop new therapeutic options for patients.
More on illi News
"Artificial intelligence has the potential to advance precision medicine in ways that seemed unimaginable just a few short years ago," said Eric Lefkofsky, Founder and CEO of Tempus. "We look forward to working with AstraZeneca to apply AI-enabled solutions to advance its robust therapeutic pipeline in an effort to help patients live longer and healthier lives."
"Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. "We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline."
About Tempus
More on illi News
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Contacts
Erin Carron
erin.carron@tempus.com
The strategic collaboration aims to optimize Tempus' AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale. Under the terms of the agreement, AstraZeneca will leverage Tempus' de-identified data and analytical tools across a broad range of capabilities. This collaboration combines Tempus' AI and machine learning capabilities for identifying novel insights with AstraZeneca's deep expertise in R&D to ultimately develop new therapeutic options for patients.
More on illi News
- Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
- ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
- Keyrenter Property Management Naperville Announces Grand Opening
- Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
- Registration for Future of Commerce 2026 is Now Open!
"Artificial intelligence has the potential to advance precision medicine in ways that seemed unimaginable just a few short years ago," said Eric Lefkofsky, Founder and CEO of Tempus. "We look forward to working with AstraZeneca to apply AI-enabled solutions to advance its robust therapeutic pipeline in an effort to help patients live longer and healthier lives."
"Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. "We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline."
About Tempus
More on illi News
- Tony Grundler Introduces Artificial Intelligence V.S. Avatar-Ian's
- Hollywood's Elite Gather at the Annual WOW Creations Oscars Gifting Suite at the Universal Hilton
- Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
- Chicago: Mayor Brandon Johnson Appoints Deputy Mayor Kenya Merritt as Department of Cultural Affairs and Special Events Commissioner
- City of Chicago and Choose Chicago to Lead Chicago 250 Commemoration, Celebrating the History and Soul of America
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Contacts
Erin Carron
erin.carron@tempus.com
Filed Under: Business
0 Comments
Latest on illi News
- Klincher Live at Pop's Nightclub Brings High-Energy Rock Show to Sauget Illinois
- Jeron Electronic Systems, Inc. to Showcase Area of Rescue Pro-Alert™ 480 at ISC West 2026, Booth #6130
- A Year in Love by Michael G. D'Aversa Offers Daily Celebrations of Romance and Devotion
- Mayor Brandon Johnson and Chicago City Council Honor, Celebrate, And Memorialize the Life and Legacy of the Rev. Jesse Jackson, Extend Condolences to the Jackson Family
- Tint Academy Training in Dallas Texas: Learn Window Tint & PPF Installation
- $IBG accelerates toward transformative merger with BlockFuel as $6 million raise fuels dual-industry growth strategy: N A S D A Q: IBG
- High-Growth Power Infrastructure Play Targets AI Boom: 1606 Corp. Executes Aggressive Texas Expansion Strategy: 1606 Corp. (Stock Symbol: CBDW) $CBDW
- Accelerating the Transformation into a U.S. Nuclear Fuel Cycle Leader: Frontier Nuclear and Minerals Inc. (N A S D A Q: FNUC)
- Ozz Metals Ltd Secures 1-Tonne Gold Offtake Agreement
- Jet Set: The Ultimate Coachella Afterparty
- Heritage at Manalapan Introduces New Single-Family Home Community in One of Monmouth County's Most Desirable Locations
- Compliant Workspace announces partnership with Blackpoint Cyber
- Michigan Homeowners Urged to Act on Rising Basement Waterproofing Needs Amid Severe Flood
- Event Solutions Enters New Era: Announces New Leadership
- Carlsbad Hotel Named Best of La Quinta Award Winner
- Scoop Social Co. Launches a New Era of Mobile Hospitality — One Truck, Two Experiences
- Record Sales Growth After Strategic Acquisitions; New Distribution Agreements for Established Premium Cigar Supplier: Green Leaf Innovations $GRLF
- R2 Copilot Addresses Critical Privacy Issues as Enterprise AI Spending and Security Incidents Rise
- Innovative Environmental Technologies Unveils New Website Featuring Free AI Tools for the Environmental Industry
- CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia